Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial
- PMID: 36350591
- PMCID: PMC9647561
- DOI: 10.1001/jamapsychiatry.2022.3679
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial
Abstract
Importance: Anxiety disorders are common, highly distressing, and impairing conditions. Effective treatments exist, but many patients do not access or respond to them. Mindfulness-based interventions, such as mindfulness-based stress reduction (MBSR) are popular and can decrease anxiety, but it is unknown how they compare to standard first-line treatments.
Objective: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for anxiety disorders.
Design, setting, and participants: This randomized clinical trial (Treatments for Anxiety: Meditation and Escitalopram [TAME]) included a noninferiority design with a prespecified noninferiority margin. Patients were recruited between June 2018 and February 2020. The outcome assessments were performed by blinded clinical interviewer at baseline, week 8 end point, and follow-up visits at 12 and 24 weeks. Of 430 individuals assessed for inclusion, 276 adults with a diagnosed anxiety disorder from 3 urban academic medical centers in the US were recruited for the trial, and 208 completed the trial.
Interventions: Participants were 1:1 randomized to 8 weeks of the weekly MBSR course or the antidepressant escitalopram, flexibly dosed from 10 to 20 mg.
Main outcomes and measures: The primary outcome measure was anxiety levels as assessed with the Clinical Global Impression of Severity scale (CGI-S), with a predetermined noninferiority margin of -0.495 points.
Results: The primary noninferiority sample consisted of 208 patients (102 in MBSR and 106 in escitalopram), with a mean (SD) age of 33 (13) years; 156 participants (75%) were female; 32 participants (15%) were African American, 41 (20%) were Asian, 18 (9%) were Hispanic/Latino, 122 (59%) were White, and 13 (6%) were of another race or ethnicity (including Native American or Alaska Native, more than one race, or other, consolidated owing to low numbers). Baseline mean (SD) CGI-S score was 4.44 (0.79) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protocol sample and 4.49 (0.77) vs 4.54 (0.83), respectively, in the randomized sample. At end point, the mean (SD) CGI-S score was reduced by 1.35 (1.06) for MBSR and 1.43 (1.17) for escitalopram. The difference between groups was -0.07 (0.16; 95% CI, -0.38 to 0.23; P = .65), where the lower bound of the interval fell within the predefined noninferiority margin of -0.495, indicating noninferiority of MBSR compared with escitalopram. Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalopram based on the improvement in CGI-S score. Of patients who started treatment, 10 (8%) dropped out of the escitalopram group and none from the MBSR group due to adverse events. At least 1 study-related adverse event occurred for 110 participants randomized to escitalopram (78.6%) and 21 participants randomized to MBSR (15.4%).
Conclusions and relevance: The results from this randomized clinical trial comparing a standardized evidence-based mindfulness-based intervention with pharmacotherapy for the treatment of anxiety disorders found that MBSR was noninferior to escitalopram.
Trial registration: ClinicalTrials.gov Identifier: NCT03522844.
Conflict of interest statement
Figures
Comment in
-
Potential of Control Conditions for Nonspecific Treatment-Effects in Noninferiority Trials-Reply.JAMA Psychiatry. 2023 May 1;80(5):523. doi: 10.1001/jamapsychiatry.2023.0106. JAMA Psychiatry. 2023. PMID: 36920354 No abstract available.
-
Potential of Control Conditions for Nonspecific Treatment Effects in Noninferiority Trials.JAMA Psychiatry. 2023 May 1;80(5):522-523. doi: 10.1001/jamapsychiatry.2023.0102. JAMA Psychiatry. 2023. PMID: 36920358 No abstract available.
Similar articles
-
Effects of Mindfulness Training and Exercise on Cognitive Function in Older Adults: A Randomized Clinical Trial.JAMA. 2022 Dec 13;328(22):2218-2229. doi: 10.1001/jama.2022.21680. JAMA. 2022. PMID: 36511926 Free PMC article. Clinical Trial.
-
Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial.JAMA Intern Med. 2021 Mar 1;181(3):317-328. doi: 10.1001/jamainternmed.2020.7090. JAMA Intern Med. 2021. PMID: 33315046 Free PMC article. Clinical Trial.
-
Mindfulness-based stress reduction for family carers of people with dementia.Cochrane Database Syst Rev. 2018 Aug 14;8(8):CD012791. doi: 10.1002/14651858.CD012791.pub2. Cochrane Database Syst Rev. 2018. PMID: 30106471 Free PMC article. Review.
-
Effect of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care on Back Pain and Functional Limitations in Adults With Chronic Low Back Pain: A Randomized Clinical Trial.JAMA. 2016 Mar 22-29;315(12):1240-9. doi: 10.1001/jama.2016.2323. JAMA. 2016. PMID: 27002445 Free PMC article. Clinical Trial.
-
Mindfulness and bodily distress.Dan Med J. 2012 Nov;59(11):B4547. Dan Med J. 2012. PMID: 23171754 Review.
Cited by
-
The impact of mindfulness apps on psychological processes of change: a systematic review.Npj Ment Health Res. 2024 Mar 18;3(1):14. doi: 10.1038/s44184-023-00048-5. Npj Ment Health Res. 2024. PMID: 38609511 Free PMC article. Review.
-
[Treatment resistance in anxiety disorders-Definition and treatment options].Nervenarzt. 2024 May;95(5):407-415. doi: 10.1007/s00115-024-01627-3. Epub 2024 Mar 4. Nervenarzt. 2024. PMID: 38436664 Review. German.
-
Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study).Front Psychol. 2024 Feb 7;15:1291198. doi: 10.3389/fpsyg.2024.1291198. eCollection 2024. Front Psychol. 2024. PMID: 38384348 Free PMC article.
-
Practice and proficiency of Isha Yoga for better mental health outcomes: insights from a COVID-19 survey.Front Public Health. 2024 Feb 2;12:1280859. doi: 10.3389/fpubh.2024.1280859. eCollection 2024. Front Public Health. 2024. PMID: 38371236 Free PMC article.
-
Distress tolerance as a mediator of mindfulness-based intervention for anxiety and depression: Evidence from two randomized controlled trials.Int J Clin Health Psychol. 2024 Apr-Jun;24(2):100445. doi: 10.1016/j.ijchp.2024.100445. Epub 2024 Feb 1. Int J Clin Health Psychol. 2024. PMID: 38333547 Free PMC article.
References
-
- GBD 2019 Mental Disorders Collaborators . Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3 - DOI - PMC - PubMed
-
- Croghan TW, Tomlin M, Pescosolido BA, et al. . American attitudes toward and willingness to use psychiatric medications. J Nerv Ment Dis. 2003;191(3):166-174. doi:10.1097/01.NMD.0000054933.52571.CA - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical